Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE